Sequencing and Combination Strategies with Pirtobrutinib and CAR-T Therapy in R/R CLL

Author(s):

Nitin Jain, MD,Joanna M. Rhodes, MD, MSCE

Panelists discuss how they approach treatment selection for multi-refractory chronic lymphocytic leukemia (CLL) patients, considering factors such as prior therapy responses, patient fitness, and disease characteristics to guide choices among available options, including CAR T-cell therapy, while also addressing the limitations and challenges associated with each treatment modality in their decision-making process.

EP: 1.The Current Treatment Landscape for R/R CLL

EP: 2.Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL

EP: 3.Key Patient-Specific Factors Guiding Treatment Selection in CLL

EP: 4.Tailoring Treatment Approaches for Rapid vs. Slow Disease Progression in CLL

EP: 5.Assessing Resistance to First-Line BTK Inhibitor Therapy: The Emergine Role of Testing in CLL

EP: 6.Pirtobrutinib in the Management of R/R CLL: Updates from the BRUIN Trial

EP: 7.Application of Pirtobrutinib in R/R CLL: Expert Perspectives

EP: 8.Influence of TLS Risk and Patient Preferences on Treatment Selection in Relapsed/Refractory CLL

EP: 9.Navigating treatment strategies for patients with multi-refractory CLL: CAR-T, ASCT, and PI3K Inhibitors

Now Viewing

EP: 10.Sequencing and Combination Strategies with Pirtobrutinib and CAR-T Therapy in R/R CLL

Video content above is prompted by the following:

Which treatment options do you offer to your multi-refractory CLL patients and how do you select among available therapies?
What key factors guide your decision to use CAR T-cell therapy in the R/R setting and what criteria do you use to select patients for this treatment?
What are some limitations or challenges associated with these therapies and how do you weigh these into your